D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
P2.17-27 IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab + Chemotherapy
Naiyer A. Rizvi,David R. Gandara,Ben Solomon,Anthony W. Kim,Alessandro Brunelli,Shawn W. Sun,B.J. Gitlitz,K. Tajima,W. Lin,Alan Sandler,Solange Peters +10 more
Journal Article
Early stage lung cancer--new approaches to evaluation and treatment
Thomas J. Lynch,Jeffrey A. Bogart,Walter J. Curran,Malcolm M. DeCamp,David R. Gandara,Glenwood D. Goss,Claudia I. Henschke,James R. Jett,Bruce E. Johnson,Karen Kelly,Thierry Le Chevalier,James L. Mulshine,Giorgio V. Scagliotti,Joan H. Schiller,Alice T. Shaw,Nick Thatcher,Everett E. Vokes,Douglas E. Wood,Carol S. Hart +18 more
TL;DR: “Early Stage Lung Cancer—New Approaches to Evaluation and Treatment,” held in Cambridge, MA, October 1 — 2, 2004, was convened to present and discuss recent study findings on the detection, staging, and treatment of stage I to III non–small cell lung cancer.
Journal ArticleDOI
Small cell lung cancer: current status of new chemotherapeutic agents
TL;DR: New chemotherapeutic agents, including CPT-11, topotecan, 9-aminocamptothecin, Vinorelbine (Navelbine) and Gemcitabine are introduced into the literature.
Journal Article
Gemcitabine in combination with new platinum compounds: an update.
TL;DR: Recent studies investigating gemcitabine plus carboplatin and preliminary data regarding combinations of gem citabine with the new platinum analog oxaliplatin are reviewed.
Journal ArticleDOI
1313PImmune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK
Diego Cortinovis,J. von Pawel,Kostas N. Syrigos,Julien Mazieres,Rafal Dziadziuszko,Louis Fehrenbacher,Paul Conkling,J. Goldschmidt,C.A. Thomas,Rodolfo Bordoni,Michael P. Kosty,Fadi Braiteh,Pei He,Marcus Ballinger,M. Gandhi,Hina Patel,David R. Gandara +16 more